GAMP5 in the AI Era: What FDA Auditors Expect From Your Computer System Validation Program

FDA’s draft Computer Software Assurance guidance landed in September 2022 with a message that was more paradigm shift than policy tweak. Three years on, most validation teams are still running on the old playbook — and FDA investigators know it.

That gap is exactly where Warning Letters originate. CSV deficiencies appear consistently among FDA’s top 10 cited GMP violations for pharmaceutical manufacturing, and the pattern hasn’t changed even as FDA has signaled, repeatedly, that it wants less documentation theater and more genuine risk thinking. The ISPE GAMP5 Second Edition, published in March 2022, made the same argument. If your validation program was built around the 2008 first edition, it’s already structurally outdated — not because the science changed, but because the risk framework did.

Here’s what FDA auditors are actually scrutinizing in 2026, and where AI-augmented validation approaches are starting to matter.

What Changed in GAMP5’s Second Edition (And Why It Still Hasn’t Hit Most QA Floors)

The 2008 first edition gave the industry five software categories. Category 2 — commercially available infrastructure software like operating systems and network tools — was treated as its own class. The Second Edition retired Category 2 entirely, collapsing the framework to four categories: 1 (infrastructure software), 3 (non-configured products), 4 (configured products), and 5 (custom applications). That’s not a cosmetic change. It fundamentally alters how you scope validation effort for enterprise systems.

More significantly, the Second Edition integrated guidance on cloud and SaaS platforms — something the 2008 edition had no framework for at all. Industry estimates consistently place cloud-based or SaaS deployments at well over half of new laboratory informatics implementations today. The Second Edition also tightened alignment with ICH Q10 and introduced more explicit language around scalable testing. “Scalable” is the operative word: test scope should be proportional to the risk of software failure, not to the size of your validation team or the thickness of the binder.

What the Second Edition preserves explicitly — and what hasn’t changed — is the primacy of 21 CFR Part 11 for systems handling electronic records and signatures. Published in the Federal Register on March 20, 1997, Part 11 remains the bedrock regulatory requirement for audit trails, access controls, and data integrity in electronic systems. Newer FDA guidance layers risk thinking on top of it; it doesn’t replace it.

Five Things FDA Investigators Actually Probe During a CSV Audit

Walk through enough mock audits and a pattern emerges. Investigators aren’t spending their time counting test scripts. They’re looking for five things specifically.

Is the validation scope defensible? Can you explain — with written rationale tied to a risk assessment — why certain functions were validated to a given depth? If your validation protocol covers 400 test cases for a system where fewer than 15 are actually critical to product quality decisions, you’ve documented process but not understanding. The CSA framework asks you to make and document that distinction explicitly.

Does your audit trail actually function? 21 CFR Part 11.10(e) requires audit trails that capture date, time, and user identity for any change to electronic records. Investigators test this in real time. They’ll ask you to make a change in the system and show them what the audit trail captured. Systems validated on paper but never tested operationally fail here with surprising regularity.

Who has access to what — and is that list current? User access controls under 21 CFR Part 11.10(d) require system access limited to authorized individuals. Investigators will ask for your current user list and compare it against HR records. Terminated employees with active logins are a citation waiting to happen, and they appear in Warning Letters more often than they should.

Is the system maintained in a validated state? This is change control. Most facilities validate a system competently at installation and then apply patches, configuration updates, and interface modifications without treating them as validation events. Investigators look at your change log for the past 24 months. Each change that could affect validated functions needs an impact assessment. Many organizations have the policy written; fewer have consistent execution.

Can you demonstrate data integrity for the records that matter? ALCOA+ (Attributable, Legible, Contemporaneous, Original, Accurate — plus Complete, Consistent, Enduring, and Available) is the framework FDA applies to data integrity. FDA’s data integrity guidance documents from 2016 and 2018 formalized these expectations for electronic systems. In a CSV audit, they surface every time.

The Computer Software Assurance Shift: From Documentation Mass to Risk Intelligence

FDA’s September 2022 draft guidance was titled “Computer Software Assurance for Production and Quality System Software.” The title itself is deliberate. “Assurance” replaces “validation” as the organizing concept — a signal that FDA wants to see evidence of justified confidence in system performance, not just evidence of testing activity.

The practical implication: FDA’s CSA framework asks manufacturers to concentrate validation effort where failure would have real consequence. For a LIMS generating release data, that means deep scrutiny of calculation logic, data transfer integrity, and audit trail configuration. For a scheduling tool used internally with no connection to product quality decisions, it might mean very little — just documented rationale for why no further validation is needed.

This is a materially different posture from how most pharmaceutical and biotech QA teams were trained. The shift requires genuine critical thinking at the quality system level, not just procedural execution. You can’t template your way through a CSA-aligned validation. You have to actually understand the system, its data flows, and the consequences of failure.

That’s where teams start to struggle. And it’s where AI augmentation is starting to provide real leverage.

Where AI Fits Into a Modern Validation Program

AI isn’t replacing validation engineers. But it’s changing what a validation engineer can accomplish in a given cycle — and what a well-prepared audit defense looks like.

At the practical level, AI-assisted validation tools are being used for three things right now: generating and reviewing test scripts against system requirements, scanning validation packages for common Part 11 compliance gaps before an audit, and analyzing audit trail data at scale to detect anomalies that human reviewers would miss. A system generating tens of thousands of audit trail entries per day isn’t something a QA specialist can review manually with any reliability. Pattern recognition tools trained on Part 11 requirements can flag access anomalies, timestamp irregularities, and modification patterns in hours rather than weeks.

The more significant application is in the risk assessment phase. GAMP5’s risk-based approach requires you to identify critical functions, assign risk levels, and calibrate your validation depth accordingly. Done manually, this is a subjective process that varies by team and auditor. AI tools trained on regulatory guidance, historical Warning Letters, and GAMP5 categorization criteria can generate draft risk assessments that are more consistent, more comprehensive, and faster to review than manual approaches. The human expert still owns the final judgment — but the starting point is materially stronger.

There’s a second-order consideration worth flagging explicitly: if you’re using AI tools in a GxP context — in decision support, audit trail analysis, LIMS integration, or quality system workflow — those tools may themselves require validation under GAMP5. Depending on configuration, they’ll fall into Category 4 or Category 5. The fact that a tool is AI-based doesn’t exempt it from Part 11 or GAMP5 requirements. That’s a question we get consistently, and the answer doesn’t change: novel technology, same regulatory framework.

The Practical Takeaway

Your validation program’s job is not to produce documentation. Its job is to provide justified confidence that your software performs correctly for its intended use — and to demonstrate that to an FDA investigator in real time.

Start by reviewing your current CSV packages against GAMP5 Second Edition’s four-category framework. If they were built on the 2008 edition, identify the gaps, particularly around cloud-hosted systems and the retired Category 2 logic. Map your audit trail configuration against the specific requirements of 21 CFR Part 11.10. Run a targeted mock audit focused on user access controls and change log integrity — those are where investigators concentrate and where citations cluster most predictably.

And if you’re deploying AI tools in production or quality systems, scope them into your validation program now, before an inspection forces the question.

The companies that come through CSV audits cleanly aren’t the ones with the thickest binders. They’re the ones who can walk an investigator through the reasoning behind every decision in their validation program — and field follow-up questions without opening a folder.

Written by Sam Sammane, Founder & CEO, Aurora TIC | Founder, Qalitex Group. Learn more about our team

Reserve early access to our AI audit tools Contact us

Related from our network

• ISO 17025-Accredited Lab Testing for Regulated Industries — Third-party analytical testing services for supplement, food, and cosmetic manufacturers requiring FDA-compliant data packages and CoAs.
• GMP Laboratory Services for Canadian Pharmaceutical Manufacturers — Health Canada–aligned testing and regulatory support for NHP and drug product manufacturers navigating Canadian GMP requirements.